ATYR had fallen below Nasdaq's $1 minimum bid price, but the exchange says it has regained compliance and has no outstanding deficiency notices. This resolves the listing problem, though the filing reports no change to its drug research or sales.
This removes the Nasdaq minimum-price problem that could have threatened ATYR's listing. The filing reports no change to its drug research or sales, so the benefit is limited to its listing status.
Follow aTyr Pharma Inc (ATYR) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ATYR